📖 Your Q2 Earnings Guide: Discover the Stocks ProPicks AI Highlights to Jump Post-EarningsRead more

Alpine Immune stock downgraded by Leerink Partners after Vertex acquisition

EditorEmilio Ghigini
Published 04/12/2024, 05:59 AM
ALPN
-

Friday - Leerink Partners has downgraded Alpine Immune Sciences (NASDAQ:ALPN) stock from Outperform to Market Perform, aligning with Vertex Pharmaceuticals (NASDAQ:VRTX)' acquisition offer of $65 per share. The new price target represents a significant increase from the previous $42.00 target, reflecting the terms of the proposed buyout.

The transaction, which values Alpine Immune Sciences at approximately $4.9 billion, is seen as a strategic move for Vertex. The acquisition allows Vertex to expand its expertise in clinical development and commercial infrastructure into specialty markets, particularly benefiting from Alpine's povetacicept, a treatment for IgA nephropathy (IgAN) and other B-cell mediated autoimmune diseases.

Leerink Partners' adjustment of the price target to $65 corresponds with the acquisition price offered by Vertex. The firm believes that the deal will enhance Vertex's portfolio with what could be a leading therapy in its class, with broad applications in renal and B-cell mediated autoimmune conditions.

The minimal overlap in pipeline programs between Alpine Immune Sciences and Vertex is expected to mitigate regulatory risks from the Federal Trade Commission (FTC). The closure of the deal is anticipated in the second quarter of 2024, according to company guidance, which aligns with Leerink Partners' expectations.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.